Effects of Silica and Asbestos Fibres on the Efferocytosis Capacities of Macrophages

Rennes University Hospital23 enrolled

Overview

Evaluation of the efferocytosis capacities of blood Monocyte Derived Macrophages (MDM) from patients with a history of asbestosis or silica exposure and comparison of these capacities with those of MDM from healthy donors.

Patients with a proven history or current exposure will have 4 EDTA tubes drawn, approximately 24mL of fresh whole blood for efferocytosis assessment and : * 2 x 6mL serum tubes for the assessment of Antinuclear Antibody (ANA) positivity, serum high-mobility group box 1 (HMGB1) and osteopontin for patients exposed to asbestos * 1 x 6mL serum tube for serum HMGB1 and osteopontin for patients exposed to silica

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

History of Exposure to Silica or Asbestosis Positive Testing for ANA as a Marker of Systemic Autoimmune Diseases

Interventions

Blood collectionBIOLOGICAL

4 EDTA tubes for 24 mL blood collection

Blood sampleBIOLOGICAL

2 drying tubes for 12 mL blood collection

Blood sampleBIOLOGICAL

1 drying tube for 6 mL blood collection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient older than 18 Yo * Addressed to the department of occupational disease * With a history of asbestosis or silica exposure evaluated by a dedicated questionnaire and a throughout examination of the history of occupations, according to standard procedures for the follow-up of at risk workers. * Persons who received an oral and written information on the protocol and signed the informed consent form Exclusion Criteria: * Pregnant or breastfeeding women * Subject legally protected (under judicial protection, guardianship), persons deprived of liberty

Locations (1)

CHU de Rennes

Rennes, France

Outcomes

Primary Outcomes

Efferocytosis Index (EI) calculation (%) defined as the number of efferocyte MDM / total number of MDM

Time frame: Through study completion, an average of 2 years

Secondary Outcomes

EI calculation in patients positive for ANA vs patients negative for ANA

Time frame: Through study completion, an average of 2 years

Serum concentration of HMGB1 and Osteopontin (SPP1) by ELISA

Time frame: Through study completion, an average of 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.